Latigo Biotherapeutics
52 employees
Biotech/Pharma
Series B · $285.0M
Open positions (2)
Company details
Team Size52
IndustryBiotech/Pharma
Funding
Total raised
$285.0M
Last stage
Series B
Investors
Foresite Capital
Total raised
$285.0M
Last stage
Series B
Investors
Nima Farzan
Brings more than two decades of leadership in biopharma; former CEO of Kinnate Biopharma (led $270M IPO and sale to Xoma); former President & CEO of PaxVax; holds MBA from Harvard Business School and BA in human biology from Stanford.
Desmond Padhi
Amgen veteran who headed the pharma giant's pharmacokinetics team and various therapeutic divisions for 19 years; spearheaded Latigo's growth as Westlake operating partner and served as interim CEO at launch.
Sean Harper
Amgen veteran with 16 years at the company, culminating in leading R&D; co-founding managing director at Westlake Village BioPartners, which founded and incubated Latigo in 2020.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.